BACKGROUND: Agitation is a common and distressing symptom in patients with Alzheimer's disease. Cholinesterase inhibitors improve cognitive outcomes in such patients, but the benefits of these drugs for behavioral disturbances are unclear. METHODS: We randomly assigned 272 patients with Alzheimer's disease who had clinically significant agitation and no response to a brief psychosocial treatment program to receive 10 mg of donepezil per day (128 patients) or placebo (131 patients) for 12 week...Expand abstract
- Publication status:
- Peer review status:
- Peer reviewed
- Publisher's version
- Massachusetts Medical Society Publisher's website
- The New England journal of medicine Journal website
- Publication date:
- Source identifiers:
- Local pid:
- Copyright holder:
- Massachusetts Medical Society
- Copyright date:
- From New England Journal of Medicine, Robert J. Howard, Edmund Juszczak, Clive G. Ballard, Peter Bentham, Richard G. Brown, Roger Bullock, Alistair S. Burns, Clive Holmes, Robin Jacoby, Tony Johnson, Martin Knapp, James Lindesay, John T. O'Brien, Gordon Wilcock, Cornelius Katona, Roy W. Jones, Julia DeCesare, Michaela Rodger, Donepezil for the Treatment of Agitation in Alzheimer's Disease, 357, 1382-1392. Copyright © 2007 Massachusetts Medical Society. Reprinted with permission.
Donepezil for the treatment of agitation in Alzheimer's disease.
If you are the owner of this record, you can report an update to it here: Report update to this record